Serum urate level and cancer

1989 ◽  
Vol 28 (3) ◽  
pp. 193-195 ◽  
Author(s):  
E. Lickl ◽  
G. Alth ◽  
R. Ebermann ◽  
R.H.F. Beck ◽  
K. Tuma
Keyword(s):  
Serum Urate ◽  
Serum Urate Level

scholarly journals Decrease in Serum Urate Level Is Associated With Loss of Visceral Fat in Male Gout Patients

2021 ◽  
Vol 12 ◽  
Author(s):  
Zijing Ran ◽  
Xiaomei Xue ◽  
Lin Han ◽  
Robert Terkeltaub ◽  
Tony R. Merriman ◽  
...  
Keyword(s):  
Regression Model ◽  
Visceral Fat ◽  
Multiple Linear Regression Model ◽  
Serum Urate ◽  
Multiple Regression Model ◽  
Final Visit ◽  
Visceral Fat Area ◽  
Serum Urate Level ◽  
Lowering Therapy ◽  
The Relationship

ObjectiveTo clarify the relationship between serum urate (SU) decrease and visceral fat area (VFA) reduction in patients with gout.MethodsWe retrospectively analyzed 237 male gout patients who had two sets of body composition and metabolic measurements within 6 months. Subjects included had all been treated with urate-lowering therapy (ULT) (febuxostat 20–80 mg/day or benzbromarone 25–50 mg/day, validated by the medical record). All patients were from the specialty gout clinic of The Affiliated Hospital of Qingdao University. The multiple linear regression model evaluated the relationship between change in SU [ΔSU, (baseline SU) – (final visit SU)] and change in VFA [ΔVFA, (baseline VFA) – (final visit VFA)].ResultsULT resulted in a mean (standard deviation) decrease in SU level (464.22 ± 110.21 μmol/L at baseline, 360.93 ± 91.66 μmol/L at the final visit, p <0.001) accompanied by a decrease in median (interquartile range) VFA [97.30 (81.15–118.55) at baseline, 90.90 (75.85–110.05) at the final visit, p < 0.001]. By multiple regression model, ΔSU was identified to be a significant determinant variable of decrease in VFA (beta, 0.302; p = 0.001).ConclusionsThe decrease in SU level is positively associated with reduced VFA. This finding provides a rationale for clinical trials to affirm whether ULT promotes loss of visceral fat in patients with gout.

Gout and hyperuricaemia in the USA: prevalence and trends

Rheumatology ◽  
2019 ◽  
Vol 58 (12) ◽  
pp. 2177-2180 ◽  
Author(s):  
Gurkirpal Singh ◽  
Bharathi Lingala ◽  
Alka Mithal
Keyword(s):  
Health Professional ◽  
Recent Decade ◽  
Serum Urate ◽  
Nutrition Examination Survey ◽  
Health And Nutrition ◽  
Serum Urate Level ◽  
The Us ◽  
Home Interview ◽  
The Usa ◽  
Age Adjusted Rates

Abstract Objectives Several recent observations have suggested that the prevalence of gout may be increasing worldwide, but there are no recent data from the USA. We analysed the prevalence of hyperuricaemia and gout in the US population from 2007–08 to 2015–16. Methods We studied adults ⩾20 years of age from the National Health and Nutrition Examination Survey from 2007–08 to 2015–16. Persons with gout were identified from the home interview question ‘Has a doctor or other health professional ever told you that you had gout?’ Hyperuricaemia was defined as a serum urate level >0.40 mmol/l (6.8 mg/dl) (supersaturation levels at physiological temperatures and pH). Results In 2015–16, the overall prevalence of gout among US adults was 3.9%, corresponding to a total affected population of 9.2 million. Hyperuricaemia (>0.40 mmol/l or 6.8 mg/dl) was seen in 14.6% of the US population (estimated 32.5 million individuals). No significant trends were identified in the age-adjusted prevalence of gout and hyperuricaemia. Statistical comparisons between 2007–08 and 2015–16 age-adjusted rates were not significant. Conclusion While the age-adjusted prevalence of gout and hyperuricaemia has remained unchanged in the most recent decade from 2007–08 to 2015–16, the estimated total number of persons with self-reported gout has increased from 8.3 million to 9.2 million. The age-adjusted prevalence of hyperuricaemia has declined slightly, but the total number of affected individuals is virtually identical (32.5 million in 2015–16 compared with 32.1 million in 2007–08).

How Does Whisky Lower Serum Urate Level?

2013 ◽  
Vol 28 (5) ◽  
pp. 788-790 ◽  
Author(s):  
Yang Lu ◽  
Takeo Nakanishi ◽  
Miki Fukazawa ◽  
Ikumi Tamai
Keyword(s):  
Serum Urate ◽  
Lower Serum ◽  
Serum Urate Level

One year safety and efficacy of inosine to increase the serum urate level for patients with Parkinson's disease in Japan

2017 ◽  
Vol 383 ◽  
pp. 75-78 ◽  
Author(s):  
Hirotaka Iwaki ◽  
Rina Ando ◽  
Noriyuki Miyaue ◽  
Satoshi Tada ◽  
Tomoaki Tsujii ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Serum Urate ◽  
Safety And Efficacy ◽  
Serum Urate Level ◽  
One Year

scholarly journals Facilitating equitable prevention and management of gout for Māori in Northland, New Zealand, through a collaborative primary care approach

2019 ◽  
Vol 11 (2) ◽  
pp. 117 ◽  
Author(s):  
Aniva Lawrence ◽  
Sharon Scott ◽  
Fabio Saparelli ◽  
Georgina Greville ◽  
Andrew Miller ◽  
...  
Keyword(s):  
Primary Care ◽  
New Zealand ◽  
Community Pharmacists ◽  
Community Support ◽  
Serum Urate ◽  
Acute Gout ◽  
Serum Urate Level ◽  
Diabetes Status ◽  
Urate Lowering Treatment

ABSTRACT INTRODUCTIONThe Gout Stop Programme was developed for primary care in Northland, New Zealand, to address inequitable health outcomes for Māori and Pacific people with gout. AIMThe aim of the programme was to make it easier for clinicians to prescribe urate-lowering treatment, facilitate patient adherence through education and support, and reduce barriers to gout prevention and long-term management. METHODSFrom 2015 to 2017, patients with acute gout who met inclusion criteria were prescribed treatment according to a ‘Gout Stop Pack’ option, based on renal function and diabetes status. Patients were monitored by community pharmacists. Gout educators and a Gout Kaiāwhina (community support worker) provided education and support to patients and whānau (families). Patient completion of the programme and outcomes, according to target serum urate level, were recorded. Patient experience was documented using a questionnaire and rating scale. RESULTSIn total, 160 clinicians prescribed therapy at 887 patient presentations; 71% were Māori and Pacific patients. The completion rate was 55% in this group and 84% for the non-Māori and non-Pacific group. In the Māori and Pacific group, 40% reached the target serum urate level (≤0.36 mmol L-1) in 91 days, and 26% required further titration. In the non-Māori/non-Pacific group, these rates were 51% and 19% respectively. Following programme completion, 68% of Māori and Pacific patients and 65% of non-Māori and non-Pacific patients continued to take allopurinol. The 21 patients interviewed rated the programme as excellent or very good. DISCUSSIONCulturally appropriate education and support for patients and the primary care team was essential. Collaboration between prescribers, community pharmacists and support workers reduced barriers to initiating prevention and long-term urate-lowering treatment and urate testing in this high-needs gout population.

scholarly journals Serum Urate and the Risk of Parkinson's Disease: Results From a Meta-Analysis

2013 ◽  
Vol 40 (1) ◽  
pp. 73-79 ◽  
Author(s):  
Chunhong Shen ◽  
Yi Guo ◽  
Wei Luo ◽  
Chen Lin ◽  
Meiping Ding
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Web Of Science ◽  
Meta Analysis ◽  
Serum Urate ◽  
High Serum ◽  
Protective Effects ◽  
Inclusion Criteria ◽  
Serum Urate Level

Objective:Serum urate may exert protective effects against Parkinson's disease (PD) through its antioxidant capacities. In this article, we examine the hypothesis that high serum urate levels are associated with lower risk of PD.Methods:We searched NCBI (PubMed), ISI Web of Science and EMBASE for studies that reported the risk of PD associated with serum urate. Fixed or random effects meta-analysis was used to pool results across studies, and further analysis was used to assess the effects by gender.Results:Six studies met the inclusion criteria involving a total of 33 185 participants. Overall, we found a 33% reduction in PD incidence among persons with high serum urate level (relative risk [RR]=0.67; 95% confidence interval [CI], 0.50-0.91). Subgroup analysis was performed with 20 641 men and 12 544 women included, indicating statistically significant protective effects of serum urate in men (RR=0.60; 95% CI, 0.40-0.90) but not in women. A dose-response trend of serum urate to reduce PD risk was also observed involving 11 795 participants (RR=0.77; 95% CI, 0.68-0.88). Additionally, high serum urate levels seemed to slow the clinical decline of PD patients (RR=0.56; 95% CI, 0.43-0.72).Conclusions:In light of these findings, our study confirms previous findings of a robust association between high serum urate level and PD risk, especially in men. It also suggests that long-term exposure to high serum urate may be linked to the delay of PD progression, however more well-designed investigations are needed.

Sign in / Sign up

Export Citation Format

Share Document